Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) agonists are U.S. Food and Drug Administration–approved weight loss drugs. Despite their widespread use, the sites of action through which GLP-1R agonists (GLP1RAs) affect appetite and body weight are still not fully understood. We determined whether GLP-1Rs in either GABAergic or glutamatergic neurons are necessary for the short- and long-term effects of the GLP1RA liraglutide on food intake, visceral illness, body weight, and neural network activation. We found that mice lacking GLP-1Rs in vGAT-expressing GABAergic neurons responded identically to controls in all parameters measured, whereas deletion of GLP-1Rs in vGlut2-expressing glutamatergic neurons eliminated liraglutide-induced weight loss and visceral illness and severely attenuated its effects on feeding. Concomitantly, deletion of GLP-1Rs from glutamatergic neurons completely abolished the neural network activation observed after liraglutide administration. We conclude that liraglutide activates a dispersed but discrete neural network to mediate its physiological effects and that these effects require GLP-1R expression on glutamatergic but not GABAergic neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs apparently only activate a subset of brainstem GLP-1R neurons, particularly in the NTS (65, 117).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,437
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
The mouse brain in stereotaxic coordinates
Konsman, J.-P. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 4,045 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“GLP-1R is expressed in the pancreas, heart, kidney, gastrointestinal tract, and brain (1).”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“As such, long-acting synthetic GLP-1R agonists (GLP1RAs) are useful therapeutic agents to treat type 2 diabetes (2).”
BackgroundLeptin Action on GABAergic Neurons Prevents Obesity and Reduces Inhibitory Tone to POMC Neurons
Vong, L., Ye, C., Yang, Z., Choi, B., Chua, S., & Lowell, B. B. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.028 · Cited by 1,235
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 7×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluential
Cited by
Items 101–158 of 158
Andreeva-Gateva, P. A., Hristov, M., Ivanova, N. M., Vasileva, D., Ivanova, A., Sabit, Z., Bogdanov, T. G., Apostolova, S. N., & Tzoneva, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910786 · Cited by 16
“Interestingly, some glutamatergic neurons have been found to express GLP-1 receptors, and liraglutide modulates its activities [29].”
BackgroundHunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment
Cao, Y., & Tong, Q. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100569 · Cited by 10
Neuroendocrine Control of Body Energy Homeostasis
Affinati, A. H., & Myers, M. G. (2021) · Europe PMC (PubMed Central) · Cited by 17
Lizcano, F., Sanabria, D., & Aviles, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1622186 · Cited by 9
Hsu, C.-C., Cheng, J., Hsu, P. H., Li, Y., & Cheng, K. (2022) · Pharmaceuticals · doi:10.3390/ph15070904 · Cited by 8
“Previous studies [19,20] found that GLP1 analogues significantly reduce body weight and food intake (anorexia).”
BackgroundEffects of liraglutide on ANP secretion and cardiac dynamics
Luo, S., Zuo, Y., Cui, X., Zhang, M., Jin, H., & Hong, L. (2023) · Endocrine Connections · doi:10.1530/ec-23-0176 · Cited by 8
“GLP-1R is a class of G protein-coupled receptors that can be activated by polypeptide agonists and is an effective therapeutic target for a variety of diseases (28, 29, 30, 31).”
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists
Cook, T. M., Fuller, K. N. Z., & Sandoval, D. A. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110269 · Cited by 7
Self-citationZhou, F., Jiang, L., Guo, J., Fan, Y., Pan, Q., Li, T., Sun, X., & Li, P. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231161516 · Cited by 7
Parabrachial nucleus neuron circuits that control feeding behavior and energy balance
Zhao, Z., Chen, Y., Xuan, Y., Zhou, G., & Qiu, W. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100509 · Cited by 7
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Alcaino, C., Reimann, F., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp286293 · Cited by 10
“GLP1R agonists are known to induce nausea in humans, which at least in part is due to activation of glutamatergic neurons in the AP (Adams et al., 2018).”
Elfers, C., Chichura, K. S., Ashlaw, E. F., Chepurny, O. G., Holz, G. G., Doyle, R. P., & Roth, C. L. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.035 · Cited by 8
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
“These diverse outcomes are mediated by liraglutide’s capacity to act on central and peripheral GLP-1R populations, particularly in glutamatergic neurons, where it modulates appetite and body weight without compromising glycemic benefits [58,59].”
Jiang, W., Skoug, C., Rodrigues, I., Ciabatti, E., Gribble, F. M., Reimann, F., Brierley, D. I., Holt, M. K., & Trapp, S. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102347 · Cited by 5
Coupland, C., Sun, N., Khalil, A., Karaoglu, E., Liśkiewicz, A., Liśkiewicz, D., Grandl, G., Akindehin, S., Maity‐Kumar, G., Yang, B. S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102136 · Cited by 5
“Improvements in the circulating stability of GLP-1 have enabled a deeper understanding of the target tissues and mechanisms mediating its insulinotropic and satiety-inducing effects [5,6].”
Wulff, B. S., Kuhre, R. E., Selvaraj, M., Rehfeld, J. F., Niss, K., Fels, J. J., Secher, A., Raun, K., & Gerstenberg, M. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32009 · Cited by 6
Carabelli, A., Canu, M., de Fondaumière, M., Debiossat, M., Leenhardt, J., Broisat, A., Ghezzi, C., Vanzetto, G., Fagret, D., Barone‐Rochette, G., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05511-z · Cited by 5
Gut–vagus–NTS neural pathway in controlling feeding behaviors
Chen, J. W., & Zhan, C. (2023) · Stress and Brain · doi:10.26599/sab.2023.9060033 · Cited by 6
Hes, C., Tomlinson, A. J., Michielsen, L., Murdoch, H. J., Soltani, F., Kokoeva, M. V., & Sabatini, P. V. (2025) · eLife · doi:10.7554/elife.106217 · Cited by 9
“While expressed across the central nervous system, GLP1R expression is particularly enriched in DVC neurons ( Adams et al., 2018 ), and it is the DVC that mediates many of the effects of GLP1R agonists ( Huang et al., 2024 ).”
Refractory Nausea and Vomiting Due to Central Nervous System Injury: A Focused Review
Stoica, S., Hogge, C. J., & Theeler, B. J. (2025) · Life · doi:10.3390/life15071021 · Cited by 6
Choudhury, I., Ward, J. H., Mahesh, S., Alam, U., Azmi, S., & Anson, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.02.010 · Cited by 5
Alsanea, S., Alkofide, H., Almadi, B., Almohammed, O. A., Alwhaibi, A. M., Alrabiah, Z., & Kalagi, N. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.009 · Cited by 5
Zapata, R. C., Zhang, D., Yoon, D., Nasamran, C. A., Chilin-Fuentes, D., Libster, A. M., Chaudry, B. S., Valencia, M. L., Ponnalagu, D., Singh, H., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101794 · Cited by 5
Hu, S.-J., Loureiro, A., & Zhang, C. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.08.003 · Cited by 3
“Distinct GLP-1R circuits, such as those in cNTS and hypothalamus, can suppress appetite through non-aversive, satiety-like mechanisms [18,42-45].”
GPR75 in glutamatergic neurons regulates body weight
Wyler, S. C., Gahlot, S., Bideyan, L., Brown, K. A., Schiavo, J. K., Galvan, M., Thomas, S., Tinajero, A., Khan, A., Merchant, W., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117011 · Cited by 5
“41–44,48–50,52– 56,58 Thus, one can imagine that deletion of GPR75 in vGlut2 neurons can reduce neuronal activity with loss of G q/11 signaling, thereby leading to increased food intake.”
Zhang, J., Li, T., Wu, Q., Qin, Z., Wei, B., Wu, R., Guo, X., Xiao, H., & Wu, W. (2022) · Toxins · doi:10.3390/toxins14060389 · Cited by 3
Zimmermann, T., Bleymehl, K., Haebel, P., Perens, J., Roostalu, U., Hecksher‐Sørensen, J., Doerr, J., Jarosch, S., Lam, D. D., Klein, H., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102326 · Cited by 5
“As survodutide enters the circumventricular organs (CVOs), it triggers a neuronal activation pattern that is known to alter food intake through downstream projections, a mechanism common to GLP-1R agonists [23,41 — 43].”
Bashaw, A. G., Roman-Ortiz, C., Gao, S. X., Schier, L. A., Borner, T., & Kanoski, S. E. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.06.006 · Cited by 5
Gut-brain axis: The role of gut microbiota in energy balance and body weight regulation
Tatık, G. P., Baran, Ö., & Dağ, A. (2025) · Clinical Science of Nutrition · doi:10.62210/clinscinutr.2024.98 · Cited by 5
“6 Suppression of food intake with the GLP-1R agonist requires GLP-1R expression on glutamatergic neurons of the CNS. 20 However, prolonging the half-life of endogenous GLP-1 by inhibiting dipeptidylpetidase-4 (DPP4) is also reported to be ineffective in modifying food intake, although it…”
Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review
Furlan, G. B., Storto, M. E. B. M., da Silva, N. A. M., Corrêa, M. M. D. S. A., de Oliveira, B. R., Filho, D. R., & Neto, D. R. (2023) · International Journal of Nutrology · doi:10.54448/ijn23105 · Cited by 2
Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
Heo, Y. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00731-z · Cited by 3
Anti-Obesity Medications in Cancer Therapy: A Comprehensive Insight
Shekhawat, R., & Mandal, C. C. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210322122829 · Cited by 3
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2
Self-citationInsights into the mechanisms of body weight control
Pereira, S. (2025) · AJP Advances in Physiology Education · doi:10.1152/advan.00091.2025 · Cited by 1
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
The central amygdala gates exogenous glucagon-like peptide 1 signals
Duran, M., Zeng, N., Cutts, E. J., POLAMARASETTY, A., Rodríguez, M., Habegger, K. M., & Hardaway, J. A. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102403 · Cited by 2
“These drugs promote insulin release, delay gastric emptying, and decrease appetite the latter of which is mediated through the central nervous system (CNS) [3 — 7].”
Hes, C., Tomlinson, A. J., Michielsen, L., Murdoch, H. J., Soltani, F., Kokoeva, M. V., & Sabatini, P. V. (2025) · eLife · doi:10.1101/2024.09.19.613879 · Cited by 3
Andreev-Andrievskiy, A. A., Александрович, М. М., Vannous, M., Fadeeva, O. V., Kazaishvili, Y. G., Куркин, Д. В., Zaslavskaya, K. Y., Beliy, P. A., Таганов, А. В., Rogozhina, E. A., et al. (2025) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2025-13-3-171-183 · Cited by 2
Neurotransmitter Co-transmission in Brain Control of Feeding and Body Weight
Cai, J., Cassidy, R. M., Morrill, J., & Tong, Q. (2021) · CRC Press eBooks · doi:10.1201/9780367823269-3 · Cited by 1
Kaur, K. K., Allahbadia, G., & Singh, M. (2021) · Journal of Endocrinology Research · doi:10.30564/jer.v3i2.3520 · Cited by 6
Hes, C., Tomlinson, A. J., Michielsen, L., Murdoch, H. J., Soltani, F., Kokoeva, M. V., & Sabatini, P. V. (2025) · eLife · doi:10.7554/elife.106217.1 · Cited by 2
Zhou, R., Duncan, K., Lopez, J., Rich, K., & Swislocki, A. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0122
Brain Glucagon-Like Peptide 1 Receptor Influence on Feeding Behavior
Williams, D. L., Anderson, L., Coiduras, I. I., & Maske, C. B. (2021) · CRC Press eBooks · doi:10.1201/9780367823269-4
The Paraventricular Nucleus of the Hypothalamus and its Role in Energy Homeostasis
Gonzalez, I. E. (2021) · Deep Blue (University of Michigan) · doi:10.7302/2850
Who knew? PPARs may act in the brain too
Seeley, R. J., & Rhodes, C. J. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00625-6
Self-citationBonner, C., Saponaro, C., Imbernón, M., Louvet, I., Deligia, E., Chen, S., Davies, I., Acosta-Montalvo, A., Moreno-Lopez, M., Wemelle, E., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5544620/v1
Modder, M., Tomás, A., Afkir, S., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., van Eenige, R., Rensen, P. C. N., Jones, B. J., & Kooijman, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16374
GPR75 in Glutamatergic Neurons Regulates Body WeightPreprint
Wyler, S. C., Gahlot, S., Bideyan, L., Schiavo, J. K., Galvan, M., Thomas, S., Tinajero, A., Khan, A., Merchant, W., Gautron, L., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5271364
Hes, C., Tomlinson, A. J., Michielsen, L., Murdoch, H. J., Soltani, F., Kokoeva, M. V., & Sabatini, P. V. (2025) · eLife · doi:10.7554/elife.106217.2 · Cited by 2
The Role of Pancreatic Preproglucagon in Regulating Local Inflammation in Mice
Zalucha, E., Hutch, C. R., Bethea, M. M., Cook, T. M., Unadkat, A., Wells, K. L., Kim, K. S., MAERZ, B., Lehrke, M., Singer, K., et al. (2026) · Cells · doi:10.3390/cells15050482
“Glp1r -GFP reporter mice were previously validated and generated as reported [18].”
Self-citationThe central amygdala integrates exogenous glucagon-like peptide 1 signalsPreprint
Duran, M., Zeng, N., Cutts, E. J., Habegger, K. M., & Hardaway, J. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716705
Malone, S. K., Glenn, A. J., Paulhamus, D. R., & Patterson, F. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105902
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“The second hypothesis is CNS-centred; GIPR appears to signal through GABAergic neurones, whereas GLP-1R agonism engages glutamatergic circuits, suggesting that modulation of GIPR signalling may shift the inhibitory-excitatory balance within hypothalamic and brainstem feeding networks [93–95].”
Saponaro, C., Imbernón, M., Louvet, I., Deligia, E., Chen, S., Davies, I., Acosta-Montalvo, A., Moreno-Lopez, M., Wemelle, E., Kothegala, L., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06779-2
“These benefits involve liraglutide’s action on hypothalamic areas and the brainstem [8, 9], suggesting broader impacts on metabolic pathways beyond direct pancreatic effects.”
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
Martínez‐Corral, I., Monaco, N., Brierley, D. I., & Imbernón, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70636 · Cited by 1
Structural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
Neuroendocrine regulation of appetite and energy balance in metabolic disorders
Khatun, M. M., Sarker, M. N. A., Biswas, M. S., Podder, M. K., & Akter, S. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.09.017
“Further experimental data suggests that GLP-1 receptor-expressing glutamatergic neurons are involved in the weight-loss effects of liraglutide, underscoring the significance of central neuronal circuits in hunger suppression (Adams et al., 2018).”
Metadata
- Authors
- Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P.
- Affiliations
- University of Michigan (US)
- Harvard University (US)
- Corresponding author
- Olson, David P.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-05-18
- Volume
- 67
- Issue
- 8
- Pages
- 1538-1548
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054439
- OpenAlex
- W2803591279
- Cited by
- 159
- References
- 57
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 24 · 2023: 17 · 2022: 10 · 2021: 32 · 2020: 17 · 2019: 10 · 2018: 2
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (T32-DK-101357, DK-082480, DK-093848, DK-107652, DK-103703, DK-104999)
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, GLP-1 receptor, GLP-1 receptor agonists, glutamatergic neurons, GABAergic neurons, appetite regulation, dietary intake, weight loss, neural network activation, VGLUT2, vesicular GABA transporter
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Appetite Depressants, Energy Intake, Hypoglycemic Agents, Hypothalamus, Male, Mice, Transgenic, Nerve Net, Nerve Tissue Proteins, Neurons, Obesity, Random Allocation, Recombinant Fusion Proteins, Weight Loss, Genes, Reporter, Mice, Knockout, Green Fluorescent Proteins, Vesicular Inhibitory Amino Acid Transport Proteins, Vesicular Glutamate Transport Protein 2, Diet, High-Fat, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.